IAS News and Literature Updates:
September/October 2017
From the President's Desk:
Yuji Matsuzawa

Following up on my earlier message about The World Heart Federation (WHF) 2nd Global Summit on Circulatory Health, held in Singapore, July 12-13, 2017, I would like to share with you the comments and concerns of the WHF regarding a new initiative funded solely by Philip Morris International.

The WHF has invited the leadership of all the professional societies who attended the Global Summit for Circulatory Health in Singapore earlier this year to sign the letter below addressed to the Editor of The Lancet.

> Complete Article <

Antonio M. Gotto, Jr. Prize in Atherosclerosis Research 
Nomination Deadline: January 15, 2018

The aim of the Gotto Prize is to encourage basic, clinical, and translational research in areas relating to the causes, prevention, and treatment of cardiovascular disease globally. The award recipient will have provided and continues to provide outstanding scientific, medical, or organizational advancement in our ability to understand the causes and to reduce the development of atherosclerosis.

For more information Click Here

Course on Identifying and Treating Severe Familial Hypercholesterolemia (Dubai, October 14-15, 2017)

IAS in collaboration with its member society, the Oman Society of Lipid and Atherosclerosis (OSLA), and with the support of the Gulf Heart Association and the Emirates Cardiac Society organized a residential Course held in Dubai on October 14-15, 2017. The Course was attended by 40 physicians from the GCC. The Workshop consisted of one day focusing on defining, identifying, and managing severe familial hypercholesterolemia; the second day was devoted to interactive case study presentations. The time provided participants with the opportunity to interact in a very intense and constructive way with an international faculty to build skills and to exchange experience. The participants were general physicians (GPs), cardiologists, endocrinologists, pediatricians, and other doctors with specialized knowledge of FH.
> See Photos Attached <

Also included in this Newsletter:

Toronto, Canada
June 9 - 12, 2018

XVIII International Symposium on Atherosclerosis
Abstract Submission Now Open!

In the News: 

Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease

By: Andreas Kousios, Panayiotis Kouis, and Andrie G Panayiotou

Cardiovascular disease (CVD) is the leading cause of death in end-stage renal disease patients (ESRD). Chronic kidney disease (CKD), even from its early asymptomatic stages and proteinuria, increases the risk for CVD substantially. Traditional CVD risk factors are highly prevalent in CKD patients; however, the use of traditional risk factor scores underestimates the CVD risk in patients with CKD.

> View Complete Commentary <

Novel Proteomic Approaches to Identify Circulating Cardiovascular Biomarkers

By: José Tuñón, Luis Blanco-Colio, Óscar Lorenzo, Jesús Egido, and José Luis Martín-Ventura

Atherothrombosis is among the leading causes of mortality and disability in the world. Although new therapies have been developed in the last years, our patients continue to have cardiovascular events, suggesting that we need new therapeutic targets. However, there is an additional issue: our patients do not share a similar evolution.

View Complete Commentary <


November 12, 2017

Joint AHA-IAS Session: Visceral Adiposity and Cardiovascular Disease
AHA Meeting Scientific Session 2017
 Anaheim, CA

View Meeting Website 

November 23-25, 2017

XXXVIII Congreso Chileno de Medicina Interna 2017“Controversias en Medicina Interna, una oportunidad de aprendizaje”
Vina del Mar, Chile

View Meeting Website

December 1-2, 2017

7th Panhellenic Symposium
of the Working Groups
of the Hellenic Atherosclerosis Society
Athens, Greece

View Meeting Website


The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission: Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Ono Pharmaceutical Co., Ltd., OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd., Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College.

>> Back To Top <<
IAS Newsletter Editors
Website Editorial Board
Scott M. Grundy, MD, PhD
Dallas, TX, USA

Associate Editors
Stefano Bellosta, PhD
Milan, Italy
Emanuela Folco, PhD
Milan, Italy
Ann Jackson, MBA
Houston, TX, USA

Website & Newsletter Editors
Elena Colombo
Milan, Italy
Yelonda Williams, BA
Dallas, TX, USA


You are a valued member of the International Atherosclerosis Society. You are receiving this email because you opted in at our website - www.athero.org

Unsubscribe <<Email Address>> from this list.

Our mailing address is:
International Atherosclerosis Society
Fondazione Giovanni Lorenzini Medical Science Foundation
viale Piave 35
Milan, Italy 20129

Add us to your address book

Copyright (C) 2017 International Atherosclerosis Society All rights reserved.

Forward this email to a friend
Update your profile